These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lui SF, Law CB, Ting SM, Li P, Lai KN. Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075 [Abstract] [Full Text] [Related]
5. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. Icardi A, Paoletti E, Molinelli G. Adv Perit Dial; 1990 Nov; 6():292-5. PubMed ID: 1982830 [Abstract] [Full Text] [Related]
6. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Saleh A, Krane NK, Caballero M, Starks E. Adv Perit Dial; 1991 Nov; 7():288-91. PubMed ID: 1680448 [Abstract] [Full Text] [Related]
7. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators. Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340 [Abstract] [Full Text] [Related]